VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Prates-Syed, WA; Chaves, LCS; Crema, KP; Vuitika, L; Lira, A; Côrtes, N; Kersten, V; Guimarães, FEG; Sadraeian, M; Barroso da Silva, FL; Cabral-Marques, O; Barbuto, JAM; Russo, M; Câmara, NOS; Cabral-Miranda, G

VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Prates-Syed, WA Chaves, LCS Crema, KP Vuitika, L Lira, A Côrtes, N Kersten, V Guimarães, FEG Sadraeian, M

Barroso da Silva, FL Cabral-Marques, O Barbuto, JAM Russo, M Câmara, NOS Cabral-Miranda, G

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Vaccines (Basel), 2021, 9, (12)
Issue Date:: 2021-11-30

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (29.94 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Prates-Syed, WA
dc.contributor.author	Chaves, LCS
dc.contributor.author	Crema, KP
dc.contributor.author	Vuitika, L
dc.contributor.author	Lira, A
dc.contributor.author	Côrtes, N
dc.contributor.author	Kersten, V
dc.contributor.author	Guimarães, FEG
dc.contributor.author	Sadraeian, M https://orcid.org/0000-0002-7384-2247
dc.contributor.author	Barroso da Silva, FL
dc.contributor.author	Cabral-Marques, O
dc.contributor.author	Barbuto, JAM
dc.contributor.author	Russo, M
dc.contributor.author	Câmara, NOS
dc.contributor.author	Cabral-Miranda, G
dc.date.accessioned	2022-03-11T20:15:29Z
dc.date.available	2021-11-20
dc.date.available	2022-03-11T20:15:29Z
dc.date.issued	2021-11-30
dc.identifier.citation	Vaccines (Basel), 2021, 9, (12)
dc.identifier.issn	2076-393X
dc.identifier.issn	2076-393X
dc.identifier.uri	http://hdl.handle.net/10453/155147
dc.description.abstract	Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Vaccines (Basel)
dc.relation.isbasedon	10.3390/vaccines9121409
dc.rights	info:eu-repo/semantics/openAccess
dc.title	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.
dc.type	Journal Article
utslib.citation.volume	9
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
utslib.copyright.status	open_access	*
dc.date.updated	2022-03-11T20:15:17Z
pubs.issue	12
pubs.publication-status	Published online
pubs.volume	9
utslib.citation.issue	12

Abstract:

Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155147